Difference between revisions of "Rizzo Lab Research"
(→HIV/AIDS) |
(→Cancer) |
||
| Line 15: | Line 15: | ||
==Cancer== | ==Cancer== | ||
* [[Cancer]] | * [[Cancer]] | ||
| + | |||
| + | |||
| + | ==== EGFR and ErbB family==== | ||
| + | |||
| + | Epidermal Growth Factor Receptor (EGFR) is a drug target for treating several types of Cancers, Including Lung and breast cansers. We are instested in targeting the Tyrosine kinase domain. | ||
| + | |||
| + | See the following paper: | ||
| + | |||
| + | Balius, T. E.; Rizzo, R. C. Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry, 2009, 48, 8435-8448. [http://pubs.acs.org/doi/abs/10.1021/bi900729a WEB] [http://rizzo.ams.sunysb.edu/~rizzo/StonyBrook/publications/rizzo019.pdf PDF] | ||
| + | |||
| + | |||
| + | ====MMPs==== | ||
| + | |||
| + | see the following paper: | ||
| + | |||
| + | Carrascal, N.; Rizzo, R. C. Calculation of Binding Free Energies for Non-zinc Chelating Pyrimidine Dicarboxamide Inhibitors with MMP-13. Bioorg. Med. Chem. Lett., 2009, 19, 47-50. [http://rizzo.ams.sunysb.edu/~rizzo/StonyBrook/publications/rizzo017.pdf PDF] | ||
==Influenza== | ==Influenza== | ||
Revision as of 10:00, 14 September 2011
PLEASE NOTE THIS PAGE IS BEING UPDATED
Contents
HIV/AIDS
GP41
viral membrane fusion inhibitor development.
See the following papers.
Strockbine, B.; Rizzo, R. C. Binding of Anti-Fusion Peptides with HIVgp41 from Molecular Dynamics Simulations: Quantitative Correlation with Experiment. Proteins: Struct. Func. Bioinformatics, 2007, 67, 630-642. PDF
McGillick, B. E.; Balius, T.E.; Mukherjee, S.; Rizzo, R. C. Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20. Biochemistry, 2010, 49 (17), 3575-3592 doi:10.1021/bi901915g PMID: 20230061 WEB PDF
Cancer
EGFR and ErbB family
Epidermal Growth Factor Receptor (EGFR) is a drug target for treating several types of Cancers, Including Lung and breast cansers. We are instested in targeting the Tyrosine kinase domain.
See the following paper:
Balius, T. E.; Rizzo, R. C. Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry, 2009, 48, 8435-8448. WEB PDF
MMPs
see the following paper:
Carrascal, N.; Rizzo, R. C. Calculation of Binding Free Energies for Non-zinc Chelating Pyrimidine Dicarboxamide Inhibitors with MMP-13. Bioorg. Med. Chem. Lett., 2009, 19, 47-50. PDF
